CNA Financial arrives at its May 4 earnings date having delivered a solid month for shareholders — but the message from the C-suite is more cautious than the tape suggests.
The most striking signal of the past six weeks isn't in the options market or the short book. It's from the executive suite. On March 13, virtually every member of the senior leadership team sold stock on the same day, at the same price of $47.03. CEO Douglas Worman led the cluster, offloading 37,062 shares for $1.74 million. CFO Scott Lindquist sold 18,603 shares, the CAO and CRO followed, and the Chief Information Officer added her own sale. Combined, the coordinated cluster netted over $5.85 million in insider proceeds over the 90-day window — all sells, zero buys. A second SVP followed on March 19. These were heavily scheduled or routine plan sales by significance scores, but the uniformity and scale are hard to ignore.
The stock has actually climbed since that cluster. From $47 at the time of the insider sales, CNA rose to $48.72 at Tuesday's close, gaining 8.6% over the past month. The question the May 4 print has to answer is whether that re-rating reflects genuine fundamental momentum or a relief bounce from the broader insurer rally. Close peer is up 2.9% on the week and has gained 5.8% — the insurance group has clearly had a strong run. and parent company (Loews holds 92% of CNA's shares) both advanced around 1.5% on Tuesday, broadly in line with CNA's 1.5% daily gain.
Options traders have turned conspicuously bullish ahead of the print. The put/call ratio has collapsed to just 0.046 — dramatically below its 20-day average of 0.18 and running 1.3 standard deviations below the mean. This is the most call-heavy options posture CNA has seen in the data window, a near-complete reversal from mid-April readings above 0.25. That isn't a hedge; it's a directional call bet. The degree of the shift warrants attention.
Short positioning has also been building quietly. Short interest climbed 11% over the past month to just under 0.9% of the free float — low in absolute terms, but the direction of travel is worth noting. Borrowing the stock remains almost frictionless: cost to borrow is 0.45%, borrow availability is ample, and the ORTEX short score of 62.7 sits well below the spike to 73.2 registered on April 23, when short interest briefly jumped to around 2.8 million shares before quickly retreating. That episode looks like a one-day technical dislocaiton rather than a sustained short build. The lending market carries no squeeze dynamic here.
The Street has been quiet on CNA for some time. The most recent analyst data — from KBW and BofA — is more than 14 months old at this point and should be treated with caution. KBW's last published target was $53, a shade above the current price; BofA's Underperform rating with a $48 target is now effectively at the money given Tuesday's close. Neither firm has re-rated since February 2025. No fresh analyst moves have been detected in the current cycle. With estimated EPS of $4.65 on revenues approaching $16 billion, the lack of active Street engagement on a major insurer ahead of earnings is itself a data point — coverage appears thin relative to the company's scale.
With earnings five days away, the setup hinges on whether the call-heavy options positioning and the month-long rally survive contact with the actual numbers.
See the live data behind this article on ORTEX.
Open CNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
